Pharmaceutical - Pharmaceutical, Pradaxa

Filter

Current filters:

PharmaceuticalPradaxa

Popular Filters

1 to 25 of 36 results

Positive early results for Boehringer Ingelheim’s investigational antidote idarucizumab

19-11-2014

The US subsidiary of German family-owned pharma major Boehringer Ingelheim has presented Phase I study…

Boehringer IngelheimCardio-vascularHematologyidarucizumabPharmaceuticalPradaxaResearch

Boehringer Ingelheim start Phase III trial on idarucizumab as antidote to Pradaxa

Boehringer Ingelheim start Phase III trial on idarucizumab as antidote to Pradaxa

12-11-2014

German family-owned drug major Boehringer Ingelheim has initiated a global Phase III study on idarucizumab,…

Boehringer IngelheimHematologyidarucizumabPharmaceuticalPradaxaResearch

FDA study shows Pradaxa reduces stroke risk but raises chances of GI bleeding

FDA study shows Pradaxa reduces stroke risk but raises chances of GI bleeding

03-11-2014

A study carried out by the US Food and Drug Administration on Pradaxa (dabigatran etexilate mesylate)…

Boehringer IngelheimHematologyPharmaceuticalPradaxaRegulationResearchUSAWarfarin Sodium

NICE recommends Pradaxa for DVT and PE

NICE recommends Pradaxa for DVT and PE

31-10-2014

In draft guidance published today, the UK health costs watchdog the National Institute for Health and…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulationUK

Boehringer Ingelheim gets two drugs approved by Scotland’s health watchdog

14-10-2014

The UK subsidiary of German family-owned pharma major Boehringer Ingelheim announced today that, following…

Boehringer IngelheimCardio-vascularDiabetesJardiancePharmaceuticalPradaxaPricingUK

Boehringer plans new real-world data on Pradaxa

01-09-2014

Five years on from the first breakthrough presentation of the pivotal RE-LY clinical trial of Pradaxa…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaResearch

Brazil and Mexico physicians’ preferences on anticoagulants

25-07-2014

Novel oral anticoagulants (NOACs) such as Bayer’s Xarelto (rivaroxaban), Boehringer Ingelheim’s Pradaxa…

BayerBoehringer IngelheimBrazilBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingMexicoPfizerPharmaceuticalPradaxaPricingXarelto

BMJ alleges Boehringer Ingelheim withheld Pradaxa dosing information from regulators

BMJ alleges Boehringer Ingelheim withheld Pradaxa dosing information from regulators

24-07-2014

German family-owned drug major Boehringer Ingelheim has been accused of withholding ‘important analyses’…

Boehringer IngelheimDabigatranGermanyHematologyPharmaceuticalPradaxaPyridinesRegulationUKUniversity of California

Bayer the latest in anticoagulant lawsuit action

Bayer the latest in anticoagulant lawsuit action

16-07-2014

German drug major Bayer is just one of the latest companies to be facing lawsuits over its anticoagulants,…

BayerBoehringer IngelheimHematologyHematologyLegalPharmaceuticalPradaxaRivaroxabanUSAWarfarin SodiumXarelto

French studies show oral anticoagulants do not cause an increased risk of severe hemorrhage despite recent deaths

French studies show oral anticoagulants do not cause an increased risk of severe hemorrhage despite recent deaths

15-07-2014

Four elderly French people who had taken Praxada to present strokes died of hemorrhages last year, although…

AnticoagulantsBoehringer IngelheimDabigatranFranceHealthcareHematologyLegalPharmaceuticalPradaxarivaroxabanVitamin K

Boehringer Ingelheim’s Pradaxa available in UK for DVT

Boehringer Ingelheim’s Pradaxa available in UK for DVT

15-07-2014

German family-owned drug major Boehringer Ingelheim says that Pradaxa (dabigatran etexilate) will be…

Boehringer IngelheimDeep vein thrombosisHematologyPharmaceuticalPradaxaRegulationUK

FDA Breakthrough status for Boehringer’s investigational Pradaxa antidote

FDA Breakthrough status for Boehringer’s investigational Pradaxa antidote

26-06-2014

The US Food and Drug Administration has granted Breakthrough Therapy designation to idarucizumab, an…

Boehringer IngelheimCardio-vascularidarucizumabPharmaceuticalPradaxaRegulationResearchUSA

High price of novel antithrombotics a major deterrent to patient access in China

High price of novel antithrombotics a major deterrent to patient access in China

10-06-2014

The high cost of therapy remains a significant barrier for uptake of novel oral anticoagulants (NOACs)…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularChinaEliquisMarkets & MarketingPharmaceuticalPradaxaPricingWarfarin SodiumXarelto

Boehringer’s Pradaxa gains added indication in Europe

Boehringer’s Pradaxa gains added indication in Europe

06-06-2014

German family-owned pharma major Boehringer Ingelheim said today that its blood thinner Pradaxa (dabigatran…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaRegulation

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

28-05-2014

German family-owned pharma major Boehringer Ingelheim says it has reached a comprehensive settlement…

Boehringer IngelheimCardio-vascularFinancialLegalPharmaceuticalPradaxaUSA

FDA finds favorable risk:benefit balance for Boehringer’s Pradaxa

18-05-2014

As part of its ongoing review, the US Food and Drug Administration last week released latest findings…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaRegulationUSA

US FDA clears Boehringer Ingelheim’s Pradaxa for additional indications

US FDA clears Boehringer Ingelheim’s Pradaxa for additional indications

07-04-2014

The US Food and Drug Administration has approved German family-owned pharma major Boehringer Ingelheim’s…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulationUSA

First human data show promise of Boehringer’s specific antidote for Pradaxa-induced anticoagulation

First human data show promise of Boehringer’s specific antidote for Pradaxa-induced anticoagulation

19-11-2013

Presented for the first time at the American Heart Association’s (AHA) Scientific Sessions, results…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisPharmaceuticalPradaxaResearchXarelto

Boehringer analysis finds better outcome for Pradaxa compared to warfarin

Boehringer analysis finds better outcome for Pradaxa compared to warfarin

08-10-2013

Boehringer Ingelheim has released new data showing better survival prognosis following a major bleeding…

Boehringer IngelheimHematologyPharmaceuticalPradaxaResearch

Boehringer Ingelheim plans to expand body of evidence for Pradaxa

04-09-2013

German family-owned drug major Boehringer Ingelheim has announced new milestones for the novel oral anticoagulant…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaResearch

Pradaxa sNDA for DVT and PE accepted by FDA

28-08-2013

The US Food and Drug Administration has accepted for review German independent drug major Boehringer…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulation

Briefs: Elan tender offer; German drug price review; Daiichi Sankyo pays milestone

19-04-2013

Ireland-based drugmaker Elan (NYSE: ELN) yesterday reported final results of its modified Dutch auction…

ActemraAmgenAnticalinBayerElanFinancialNovo NordiskPharmaceuticalPradaxaPricingProliaRegulationResearchRocheVictozaXarelto

FDA confirms views that Boehringer's Pradaxa bleeding rates no higher than for warfarin

19-03-2013

A new perspective from the US Food and Drug Administration states the agency has not changed its recommendations…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaResearch

1 to 25 of 36 results

Back to top